Thank you for your interest in the RLF-100 expanded access program.  Please note that we are no longer enrolling new sites into our expanded access program at this time.

We are humbled by the tireless effort of healthcare workers around the country to support their patients during this pandemic and thank them for their service.

Before a Request is Made

Before deciding whether this drug might be appropriate for your patient, please read our Investigator’s Brochure and Scientific Overview which detail RLF-100’s mechanism of action, indications, dosing and administration, and known adverse events.

Request Expanded Access for Aviptadil (RLF-100) for your Patients

Dear physician

Thank you for your interest in the Expanded Access Program for Aviptadil (RLF-100). This program was authorized by the FDA as an Intermediate-size Expanded Access Program.   Please note that this medication has not been approved by the FDA for any indication and is currently being studied in a clinical study of Intravenous Aviptadil for Critical COVID-19 with Respiratory Failure NCT04311697 (COVID-AIV).

Our Expanded Access Program is being managed by Clinigen.

Please note that NeuroRx and Clinigen are receiving a high volume of requests and we are working expeditiously to address these.

Due to the volume of requests, NeuroRx is unable to reply to voice mail messages on our system.

Get information about the COVID-19 Expanded Access program